Praxis Precision Medicines Inc (PRAX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.17B
Last updated: Nov 17, 2026 at 11:06 AM ET
Praxis Precision Medicines Inc (PRAX) Stock Forecast
Analysts expect Praxis Precision Medicines (PRAX) to earn -$13.47 per share in the fiscal year ending Dec 31, 2026, on revenue of $869610. Of 21 analysts, 19 rate the stock Buy or Strong Buy, 1 Hold and 1 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$9.30.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 21 ratings average 1.95, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 90% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 4 | 19.0% |
| Buy | 15 | 71.4% |
| Hold | 1 | 4.8% |
| Sell | 1 | 4.8% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 21
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 39710.9%.
- Fiscal year ending Dec 31, 2026
- -$13.47
- EPS consensus, revenue $869610
- Fiscal year ending Dec 31, 2027
- -$9.30
- EPS consensus, revenue $346.20M
- Next report
- Feb 17, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$13.47 | -$14.10 to -$12.74 | 13 | $869610 | N/A | 17 |
| Dec 31, 2027 | -$9.30 | -$16.18 to $5.25 | 18 | $346.20M | $140.23M to $674.40M | 19 |
Quarterly Estimates
The EPS consensus rises from -$4.00 for the quarter ending Dec 31, 2026 to -$3.75 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$4.00 | -$5.04 to -$1.05 | 23 | $633359 | N/A | 21 |
| Mar 31, 2027 | -$3.75 | -$5.50 to $1.94 | 11 | $31.84M | $4.00M to $190.10M | 11 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 4 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 2 |
| Quarter ending Mar 31, 2027 | 3 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$13.94.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$13.47 | -$14.02 | -$13.94 | -$13.94 | -$13.94 | N/A |
| Fiscal year ending Dec 31, 2027 | -$9.30 | -$9.50 | -$9.33 | -$9.29 | -$9.41 | N/A |
| Quarter ending Mar 31, 2027 | -$3.75 | -$3.99 | -$3.90 | -$3.89 | -$3.88 | N/A |
Frequently Asked Questions About PRAX
What is the PRAX stock forecast?
Consensus analyst estimates put Praxis Precision Medicines's EPS at -$13.47 for the fiscal year ending Dec 31, 2026, on revenue of $869610. The consensus rating from 21 analysts is Buy.
How do analysts rate PRAX stock?
Of 21 analysts covering Praxis Precision Medicines, 4 rate it Strong Buy, 15 Buy, 1 Hold, 1 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from PRAX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$13.47, with estimates from -$14.10 to -$12.74 from 13 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$9.30, with estimates from -$16.18 to $5.25 from 18 analysts.
What revenue do analysts expect from Praxis Precision Medicines next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $869610. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $346.20M, with estimates from $140.23M to $674.40M.
How many analysts cover PRAX?
21 analysts rate Praxis Precision Medicines stock, and 13 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PRAX pages: Overview, Earnings, Forecast, Financials, Competitors